Comparison of efficacy between adalimumab 80mg every other week vs 40mg every week in Crohn's disease(WAVE-K study)
Not Applicable
- Conditions
- Crohn's disease
- Registration Number
- JPRN-UMIN000023871
- Lead Sponsor
- Fukuoka University Chikushi Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who have symptomatic stenosis Patients who have fistula Patients who are considered inadequate by investigator
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Harvey Bradshaw Index remission (<4) rate at week 52
- Secondary Outcome Measures
Name Time Method Serum ADA/AAA concentration at baseline and week 52 Safety profile through 52 weeks